KR20250005979A - 화합물, 알데히드데히드로게나아제2 활성화제, 의약 조성물, 그리고 치료 및/또는 예방약 - Google Patents
화합물, 알데히드데히드로게나아제2 활성화제, 의약 조성물, 그리고 치료 및/또는 예방약 Download PDFInfo
- Publication number
- KR20250005979A KR20250005979A KR1020247030355A KR20247030355A KR20250005979A KR 20250005979 A KR20250005979 A KR 20250005979A KR 1020247030355 A KR1020247030355 A KR 1020247030355A KR 20247030355 A KR20247030355 A KR 20247030355A KR 20250005979 A KR20250005979 A KR 20250005979A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- mmol
- prodrug
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2022-070667 | 2022-04-22 | ||
| JP2022070667 | 2022-04-22 | ||
| PCT/JP2023/015870 WO2023204292A1 (ja) | 2022-04-22 | 2023-04-21 | 化合物、アルデヒドデヒドロゲナーゼ２活性化剤、医薬組成物、並びに治療及び／又は予防薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250005979A true KR20250005979A (ko) | 2025-01-10 |
Family
ID=88419993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247030355A Pending KR20250005979A (ko) | 2022-04-22 | 2023-04-21 | 화합물, 알데히드데히드로게나아제2 활성화제, 의약 조성물, 그리고 치료 및/또는 예방약 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250084036A1 (https=) |
| EP (1) | EP4512468A4 (https=) |
| JP (1) | JPWO2023204292A1 (https=) |
| KR (1) | KR20250005979A (https=) |
| CN (1) | CN118591526A (https=) |
| AR (1) | AR129100A1 (https=) |
| AU (1) | AU2023257780A1 (https=) |
| CA (1) | CA3243949A1 (https=) |
| IL (1) | IL313420A (https=) |
| MX (1) | MX2024007847A (https=) |
| TW (1) | TW202345820A (https=) |
| WO (1) | WO2023204292A1 (https=) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008112164A (ja) | 2006-10-30 | 2008-05-15 | Xerox Corp | 置換ビフェニルジアミンを含有する感光体およびそれを形成する方法 |
| JP2014160185A (ja) | 2013-02-20 | 2014-09-04 | Fuji Xerox Co Ltd | 画像形成装置 |
| JP2015127137A (ja) | 2013-11-26 | 2015-07-09 | 大日本印刷株式会社 | ウィンドウフィルム |
| CN108864034A (zh) | 2018-06-04 | 2018-11-23 | 中国人民解放军第二军医大学 | 酰胺类醛脱氢酶激动剂、其合成方法及用途 |
| JP2019151241A (ja) | 2018-03-05 | 2019-09-12 | トヨタ紡織株式会社 | 乗物用シート |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110105602A2 (en) | 2007-03-08 | 2011-05-05 | Daria Mochly-Rosen | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof |
| WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| HUE051255T2 (hu) | 2014-02-19 | 2021-03-01 | Aviv Therapeutics Inc | Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére |
| KR20200115474A (ko) | 2018-01-31 | 2020-10-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Aldh2 활성화제 |
| WO2022092310A1 (ja) * | 2020-11-02 | 2022-05-05 | 株式会社アークメディスン | 化合物、アルデヒドデヒドロゲナーゼ２活性化剤、医薬組成物、並びに治療及び／又は予防薬 |
-
2023
- 2023-04-21 JP JP2024516325A patent/JPWO2023204292A1/ja active Pending
- 2023-04-21 CN CN202380018326.4A patent/CN118591526A/zh active Pending
- 2023-04-21 TW TW112114876A patent/TW202345820A/zh unknown
- 2023-04-21 EP EP23791940.2A patent/EP4512468A4/en active Pending
- 2023-04-21 KR KR1020247030355A patent/KR20250005979A/ko active Pending
- 2023-04-21 CA CA3243949A patent/CA3243949A1/en active Pending
- 2023-04-21 MX MX2024007847A patent/MX2024007847A/es unknown
- 2023-04-21 IL IL313420A patent/IL313420A/en unknown
- 2023-04-21 WO PCT/JP2023/015870 patent/WO2023204292A1/ja not_active Ceased
- 2023-04-21 US US18/728,707 patent/US20250084036A1/en active Pending
- 2023-04-21 AU AU2023257780A patent/AU2023257780A1/en active Pending
- 2023-04-21 AR ARP230100953A patent/AR129100A1/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008112164A (ja) | 2006-10-30 | 2008-05-15 | Xerox Corp | 置換ビフェニルジアミンを含有する感光体およびそれを形成する方法 |
| JP2014160185A (ja) | 2013-02-20 | 2014-09-04 | Fuji Xerox Co Ltd | 画像形成装置 |
| JP2015127137A (ja) | 2013-11-26 | 2015-07-09 | 大日本印刷株式会社 | ウィンドウフィルム |
| JP2019151241A (ja) | 2018-03-05 | 2019-09-12 | トヨタ紡織株式会社 | 乗物用シート |
| CN108864034A (zh) | 2018-06-04 | 2018-11-23 | 中国人民解放军第二军医大学 | 酰胺类醛脱氢酶激动剂、其合成方法及用途 |
Non-Patent Citations (14)
| Title |
|---|
| 비특허문헌 1: Blood (2013) 122 (18): 3206-3209 |
| 비특허문헌 10: Gastroenterology (2016) 151: 860-869 |
| 비특허문헌 11: Carcinogenesis (2020) 41: 194-202 |
| 비특허문헌 12: International Journal of Oncology (2008) 32: 945-973 |
| 비특허문헌 13: Science Translational Medicine (2014) 6: 251 ra118 |
| 비특허문헌 14: Oxidative Medicine and Cellular Longevity (2021) 2021: ID1641717 |
| 비특허문헌 2: Journal of Bone and Mineral Research (2012) 27 (9): 2015-2023 |
| 비특허문헌 3: Nutrition & Diabetes (2016) 6, e210 |
| 비특허문헌 4: Redox Biology (2019) 24: 101205 |
| 비특허문헌 5: Journal of Hepatology (2015) 62: 647-656 |
| 비특허문헌 6: Biochemical and Biophysical Research Communications (2020) 522: 518-524 |
| 비특허문헌 7: Pharmacological Research (2017) 115: 96-106 |
| 비특허문헌 8: Biochemical and Biophysical Research Communications (2000) 273: 192-196 |
| 비특허문헌 9: Neurology (2014) 82: 419-426 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023204292A1 (ja) | 2023-10-26 |
| IL313420A (en) | 2024-08-01 |
| US20250084036A1 (en) | 2025-03-13 |
| EP4512468A4 (en) | 2026-04-08 |
| MX2024007847A (es) | 2024-07-09 |
| AR129100A1 (es) | 2024-07-17 |
| CA3243949A1 (en) | 2025-06-17 |
| JPWO2023204292A1 (https=) | 2023-10-26 |
| EP4512468A1 (en) | 2025-02-26 |
| AU2023257780A1 (en) | 2024-07-04 |
| TW202345820A (zh) | 2023-12-01 |
| CN118591526A (zh) | 2024-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101616915B (zh) | 调控激酶级联的组合物以及方法 | |
| KR102007633B1 (ko) | 신규 페닐 프로피온 산 유도체 및 이의 용도 | |
| JP5822840B2 (ja) | 眼疾患処置薬 | |
| CN116348449B (zh) | 化合物、乙醛脱氢酶2激活剂、医药组合物、以及治疗及/或预防药 | |
| JP2024505732A (ja) | ピリドピリミジノン系誘導体及びその製造方法と使用 | |
| JP2019535778A (ja) | 四置換アルケン化合物及び乳がんを治療するためのその使用 | |
| CN111148735B (zh) | 含氮杂芳基化合物及其药物用途 | |
| JP7551217B2 (ja) | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤として有用な新規ビアリール誘導体及びその使用 | |
| WO2017016523A1 (zh) | 靶向idh2突变的抗肿瘤化合物及其使用方法 | |
| KR20250005979A (ko) | 화합물, 알데히드데히드로게나아제2 활성화제, 의약 조성물, 그리고 치료 및/또는 예방약 | |
| KR102377981B1 (ko) | 폐 섬유증 치료용 조성물 | |
| HK40121025A (en) | Compound, aldehyde dehydrogenase 2 activator,pharmaceutical composition, and treatment and/or preventative drug | |
| RU2846527C1 (ru) | Соединение, средство, активирующее альдегиддегидрогеназу 2, фармацевтическая композиция и лекарственное средство для лечения и/или профилактики | |
| RU2808433C1 (ru) | Новое биарильное производное, применяемое в качестве ингибитора диацилглицерол-ацилтрансферазы 2, и его применение | |
| HK40096971A (en) | Compound, aldehyde dehydrogenase 2 activator, pharmaceutical composition, and treatment and/or preventative drug | |
| HK1143811A (en) | Oxadiazolidinedione compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |